JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB23423

Anti-cIAP2 antibody

5

(7 Reviews)

|

(14 Publications)

Rabbit Polyclonal cIAP2 antibody. Suitable for WB, ICC/IF and reacts with Human samples. Cited in 14 publications.

View Alternative Names

API2, MIHC, RNF49, BIRC3, Baculoviral IAP repeat-containing protein 3, Apoptosis inhibitor 2, Cellular inhibitor of apoptosis 2, IAP homolog C, Inhibitor of apoptosis protein 1, RING finger protein 49, RING-type E3 ubiquitin transferase BIRC3, TNFR2-TRAF-signaling complex protein 1, C-IAP2, hIAP-1, hIAP1

4 Images
Immunocytochemistry/ Immunofluorescence - Anti-cIAP2 antibody (AB23423)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-cIAP2 antibody (AB23423)

ICC/IF image of ab23423 stained human HeLa cells. The cells were methanol fixed (5 min) and incubated with the antibody (ab23423, 1μg/ml) for 1h at room temperature. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Image-iTTM FX Signal Enhancer was used as the primary blocking agent, 5% BSA (in TBS-T) was used for all other blocking steps. DAPI was used to stain the cell nuclei (blue). Alexa Fluor® 594 WGA was used to label plasma membranes (red).

Immunocytochemistry/ Immunofluorescence - Anti-cIAP2 antibody (AB23423)
  • ICC/IF

Unknown

Immunocytochemistry/ Immunofluorescence - Anti-cIAP2 antibody (AB23423)

ab23423 staining cIAP2 in HeLa cells treated with TMCB (ab120289), by ICC/IF. Decrease in cIAP2 expression correlates with increased concentration of TMCB, as described in literature.
The cells were incubated at 37°C for 10 minutes in media containing different concentrations of ab120289 (TMCB) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab23423 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

Functional Studies - Anti-cIAP2 antibody (AB23423)
  • FuncS

Unknown

Functional Studies - Anti-cIAP2 antibody (AB23423)

HeLa cells were incubated at 37°C for 24h with vehicle control (0 μM) and different concentrations of TMCB (ab120289). Decreased expression of cIAP2 in HeLa cells correlates with an increase in TMCB concentration, as described in literature.

Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 40μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab23423 at 2 μg/ml and ab1801 at 2 μg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

Western blot - Anti-cIAP2 antibody (AB23423)
  • WB

Unknown

Western blot - Anti-cIAP2 antibody (AB23423)

A doublet was observed in Daudi, Ramos and Raji whole cell lysates (lanes 1, 4 and 5). This data suggests that ab23423 might react with both cIAP1 and cIAP2 proteins. The predicted molecular weights of cIAP1 and cIAP2 are 69-kDa and 68-kDa respectively. Abcam welcomes customer feedback and would appreciate any comments regarding this product and the data presented above.

All lanes:

Western blot - Anti-cIAP2 antibody (ab23423) at 1 µg/mL

Lane 1:

Daudi (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg/mL

Lane 2:

MOLT4 (Human acute lymphoblastic leukemia cell line) Whole Cell Lysate at 10 µg/mL

Lane 3:

Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg/mL

Lane 4:

Ramos (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg/mL

Lane 5:

Raji (Human Burkitt's lymphoma cell line) Whole Cell Lysate at 10 µg/mL

Lane 6:

HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate at 10 µg/mL

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-preadsorbed-ab97080'>ab97080</a>) at 1/5000 dilution

Predicted band size: 68 kDa

Observed band size: 150 kDa,35 kDa,73 kDa,75 kDa

true

Exposure time: 8min

Key facts

Host species

Rabbit

Clonality

Polyclonal

Isotype

IgG

Carrier free

No

Reacts with

Human

Applications

WB, ICC/IF

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

The immunogen used for this product shares 85% homology with cIAP1. Cross-reactivity with this protein has not been confirmed experimentally.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1 µg/mL", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1 µg/mL", "ICCIF-species-notes": "<p></p>" }, "Mouse": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Rat": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Chicken": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" }, "Dog": { "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Storage buffer
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 1% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CIAP2 also called E3 ubiquitin-protein ligase and encoded by the BIRC3 gene functions to inhibit apoptosis. This protein belongs to the inhibitors of apoptosis (IAP) family and is around 69 kDa in mass. cIAP2 is widely expressed in various tissues including the epithelial and lymphoid cells. It operates mechanically by ubiquitinating substrates marking them for proteasomal degradation which is key in preventing cell death and maintaining cellular homeostasis.
Biological function summary

CIAP2 serves as a regulator in cell survival by functioning within signaling cascades. It participates in the formation of the TNF receptor complex which influences the NF-κB signaling pathway and inflammation response. By interacting with several proteins cIAP2 modulates downstream signaling effects that can influence immune responses and cellular proliferation helping cells adapt and survive stressful conditions.

Pathways

CIAP2 plays roles in both the NF-κB and the MAPK signaling pathways. Within these pathways cIAP2 interacts closely with proteins such as TRAF2 and RIP1. In the NF-κB pathway it helps in the regulation of inflammatory responses while in the MAPK pathway it contributes to cell growth and differentiation processes. These pathways highlight its function in regulating immune system responses and cell adaptability.

CIAP2 maintains connections with cancer and chronic inflammation. Abnormal expression or mutations of cIAP2 can lead to tumorigenesis due to disrupted apoptotic control linking it closely to cancers like lymphomas and leukemias. Additionally cIAP2 influences inflammatory diseases like Crohn's disease through its interactions with proteins such as NOD2 which further impacts the disease pathology. Proper regulation of cIAP2 is essential in avoiding unwanted cell survival and excessive inflammation highlighting its significance in various pathological conditions.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Multi-functional protein which regulates not only caspases and apoptosis, but also modulates inflammatory signaling and immunity, mitogenic kinase signaling and cell proliferation, as well as cell invasion and metastasis. Acts as an E3 ubiquitin-protein ligase regulating NF-kappa-B signaling and regulates both canonical and non-canonical NF-kappa-B signaling by acting in opposite directions : acts as a positive regulator of the canonical pathway and suppresses constitutive activation of non-canonical NF-kappa-B signaling. The target proteins for its E3 ubiquitin-protein ligase activity include : RIPK1, RIPK2, RIPK3, RIPK4, CASP3, CASP7, CASP8, IKBKE, TRAF1, and BCL10. Acts as an important regulator of innate immune signaling via regulation of Toll-like receptors (TLRs), Nodlike receptors (NLRs) and RIG-I like receptors (RLRs), collectively referred to as pattern recognition receptors (PRRs). Protects cells from spontaneous formation of the ripoptosome, a large multi-protein complex that has the capability to kill cancer cells in a caspase-dependent and caspase-independent manner. Suppresses ripoptosome formation by ubiquitinating RIPK1 and CASP8.
See full target information BIRC3

Publications (14)

Recent publications for all applications. Explore the full list and refine your search

EJHaem 6:e70127 PubMed40801055

2025

Targeted Degradation of Class 1 HDACs With PROTACs is Highly Effective at Inducing DLBCL Cell Death.

Applications

Unspecified application

Species

Unspecified reactive species

Abdullah Alraddadi,Joshua P Smalley,Wael Alzahrani,Anes Saleh,Fares Al-Mansour,Buwei He,Thong H Cao,Sandrine Jayne,Martin Dyer,James T Hodgkinson,Donald J L Jones,Shaun M Cowley,Salvador Macip

EMBO molecular medicine 17:645-678 PubMed39972068

2025

Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Nozomi Tomimatsu,Luis Fernando Macedo Di Cristofaro,Suman Kanji,Lorena Samentar,Benjamin Russell Jordan,Ralf Kittler,Amyn A Habib,Jair Machado Espindola-Netto,Tamara Tchkonia,James L Kirkland,Terry C Burns,Jann N Sarkaria,Andrea Gilbert,John R Floyd,Robert Hromas,Weixing Zhao,Daohong Zhou,Patrick Sung,Bipasha Mukherjee,Sandeep Burma

International journal of molecular sciences 24: PubMed37895085

2023

Quaternary Benzophenanthridine Alkaloids Act as Smac Mimetics and Overcome Resistance to Apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Petra Kulíšková,Lucie Vašátková,Iva Slaninová

iScience 25:103649 PubMed35024584

2022

Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52.

Applications

Unspecified application

Species

Unspecified reactive species

Dajiang Li,Morgan G Dewey,Li Wang,Shane D Falcinelli,Lilly M Wong,Yuyang Tang,Edward P Browne,Xian Chen,Nancie M Archin,David M Margolis,Guochun Jiang

FEBS open bio : PubMed33484626

2021

The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.

Applications

Unspecified application

Species

Unspecified reactive species

Gertrud Knoll,Martin Ehrenschwender

Molecular cell 77:970-984.e7 PubMed31982308

2020

Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28.

Applications

Unspecified application

Species

Unspecified reactive species

Ines Müller,Elwira Strozyk,Sebastian Schindler,Stefan Beissert,Htoo Zarni Oo,Thomas Sauter,Philippe Lucarelli,Sebastian Raeth,Angelika Hausser,Nader Al Nakouzi,Ladan Fazli,Martin E Gleave,He Liu,Hans-Uwe Simon,Henning Walczak,Douglas R Green,Jiri Bartek,Mads Daugaard,Dagmar Kulms

Endocrine-related cancer 27:163-174 PubMed31935194

2020

Effects of epigenetic pathway inhibitors on corticotroph tumour AtT20 cells.

Applications

Unspecified application

Species

Unspecified reactive species

K E Lines,P Filippakopoulos,M Stevenson,S Müller,H E Lockstone,B Wright,S Knapp,D Buck,C Bountra,R V Thakker

Oncology letters 19:2043-2052 PubMed32194701

2020

Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-κB signaling pathway in liver cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Jianping Lian,Yuanhua Zou,Ling Huang,Hao Cheng,Kai Huang,Junquan Zeng,Longhua Chen

Experimental hematology & oncology 9:1 PubMed31908904

2020

The SMAC mimetic LCL-161 selectively targets JAK2 mutant cells.

Applications

Unspecified application

Species

Unspecified reactive species

Brianna M Craver,Thanh Kim Nguyen,Jenny Nguyen,Hellen Nguyen,Christy Huynh,Sarah J Morse,Angela G Fleischman

Cell reports 4:764-75 PubMed23972990

2013

Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch.

Applications

Unspecified application

Species

Unspecified reactive species

Vineshkumar Thidil Puliyappadamba,Sharmistha Chakraborty,Sandili S Chauncey,Li Li,Kimmo J Hatanpaa,Bruce Mickey,Shayan Noorani,Hui-Kuo G Shu,Sandeep Burma,David A Boothman,Amyn A Habib
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com